NCT04863365View on ClinicalTrials.gov

A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

PHASE3UnknownINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

Placebo ophthalmic solution

A matching placebo ophthalmic solution, 3 drops daily, 28 days

DRUG

PHP-201 ophthalmic solution

PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days

Trial Locations (1)

Unknown

Seoul National University Hopsital, Seoul

Sponsors

Lead Sponsor

pH Pharma
All Listed Sponsors
lead

pH Pharma

INDUSTRY